The three-year collaboration will try to identify biomarkers that can eventually be used for targeted diagnostics and therapies.
The firm previously held rights to develop and commercialize ERAS-0015 in territories outside of China, Hong Kong, and Macau.
The $550 million convertible senior notes offering was upsized from a previously announced offering of $350 million.
The new financing was led by Venrock Healthcare Capital Partners with participation from other new and existing investors.
NEW YORK – The US Food and Drug Administration on Tuesday approved GSK's Wellcovorin (leucovorin calcium) as a treatment for adult and pediatric patients with cerebral folate deficiency who harbor ...
NEW YORK – Ohio State University researchers are using urine samples to understand bladder cancer patients' tumor microenvironments in several ongoing clinical trials, and they're confident the method ...
NEW YORK – Lyell Immunopharma has raised the second half of its planned $100 million private placement it launched last year, the company said Monday. The initial purchase agreement in July 2025 ...
The firm also said this week that it plans to submit data to the FDA from an adjuvant trial of giredestrant in ER-positive, HER2-negative breast cancer.
The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results